This is a type of lung cancer that starts in the cells that line the air sacs in your lungs. It's the most common kind of lung cancer found in people who have never smoked. It's called adenocarcinoma because the cancer cells look like they come from glands.
Every report comes from a Lived member, sent anonymously.
Have you tried Keytruda (Pembrolizumab) for Lung Adenocarcinoma?
Lung adenocarcinoma is a cancer that starts in the lung's glandular cells, the cells lining the tiny air sacs that make mucus and other fluids. It is the most common type of non-small cell lung cancer, the larger of the two main groups of lung cancer. The other group, small cell lung cancer, grows and is treated differently, so knowing the type matters from the start. In its early stages, lung adenocarcinoma often causes no symptoms, and it is sometimes found on a chest x-ray or CT scan done for another reason. As it grows, it can cause a cough that doesn't go away, chest discomfort, shortness of breath, coughing up blood, hoarseness, tiredness or weight loss without a clear reason. Because these symptoms overlap with many common illnesses, the cancer may not be recognized until it is advanced. Many adenocarcinomas carry a specific gene change that drives their growth. That is why testing the tumor itself, not just confirming the diagnosis, has become central to choosing treatment.
Lung adenocarcinoma develops when damage builds up in the DNA of lung cells and they begin to grow out of control. Smoking is the most important risk factor. Most adenocarcinomas occur in people who smoke or used to smoke, and the risk rises the earlier someone started, the more they smoked and the longer they smoked. Quitting lowers the risk compared with continuing, although it stays higher than in people who never smoked. Adenocarcinoma is also the most common lung cancer in people who have never smoked. It is more common in women than in men and tends to appear at younger ages than other lung cancer types. Radon, a naturally occurring radioactive gas that can collect indoors, especially in basements, is the leading cause of lung cancer among people who don't smoke. Secondhand smoke, workplace exposure to substances such as asbestos, earlier radiation treatment to the chest, air pollution and a family history of lung cancer also raise risk. A risk factor raises the odds without deciding the outcome. Many people with risk factors never develop lung cancer, and some people diagnosed with it have no known risk factor at all.
Diagnosis usually begins with imaging. A chest x-ray may show a spot, and a CT scan, which builds detailed cross-sectional pictures from x-rays, shows a tumor's size and location more clearly. Imaging can raise strong suspicion, but only a biopsy confirms cancer. The sample may be taken with a thin needle guided through the chest wall by CT, or through a bronchoscope, a thin flexible tube passed through the mouth or nose into the airways. A pathologist then examines the cells under a microscope to identify the type of cancer. Two further steps shape the treatment plan. Staging shows whether the cancer is limited to the lung or has spread, using tests such as a PET scan (which highlights areas of high sugar use, typical of cancer), an MRI of the brain and sampling of the lymph nodes in the center of the chest. Biomarker testing, also called molecular testing, checks the tumor for changes in genes such as EGFR (epidermal growth factor receptor) and ALK (anaplastic lymphoma kinase), along with several other genes, that can be matched to targeted medicines, and for a protein called PD-L1 that helps predict how well immunotherapy may work. When tissue is scarce, a blood test that looks for tumor DNA (sometimes called a liquid biopsy) can help find these changes. For people at higher risk, screening can find lung cancer before symptoms appear. In the United States, a yearly low-dose CT scan is recommended for adults aged 50 to 80 who have a 20 pack-year smoking history and who still smoke or quit within the past 15 years. A pack-year equals smoking one pack a day for a year, so a pack a day for 20 years or two packs a day for 10 years both count as 20 pack-years.
Treatment depends mainly on the stage of the cancer, the results of biomarker testing and a person's overall health. Most plans combine more than one approach. When the cancer can be removed, surgery to take out the tumor, usually along with the lobe of lung that contains it, offers the best chance of cure. That includes cancer limited to the lung and some cancer that has reached nearby lymph nodes. Chemotherapy, sometimes combined with immunotherapy, may be given before surgery, after it to lower the chance that the cancer returns, or both, and some people with a targetable gene change receive a targeted drug after surgery. Because the choice of treatment before surgery is made early, biomarker results matter at this stage too. For people who cannot have surgery or choose not to, a precisely focused, high-dose form of radiation called stereotactic body radiation therapy is an alternative. When the cancer has spread within the chest in a way surgery cannot remove, chemotherapy and radiation are usually given together, often followed by immunotherapy or a targeted drug. For advanced or returning adenocarcinoma, biomarker results largely decide the first treatment. If the tumor has a targetable gene change, a matched targeted drug, usually a daily pill, can shrink the cancer and keep it under control, for a length of time that varies from person to person. For example, osimertinib (Tagrisso) is used for tumors with common EGFR changes. These cancers often find ways around a targeted drug eventually, so further testing and a change of treatment may follow. Without a targetable change, treatment usually involves immunotherapy, such as pembrolizumab (Keytruda), which helps the immune system recognize and attack cancer, often combined with chemotherapy. Immunotherapy can also cause the immune system to attack healthy organs, such as the lungs, bowel, liver or hormone glands, and these effects can be serious. Radiation and other local treatments can also relieve specific problems, such as pain or a blocked airway. Palliative care, which focuses on symptoms, comfort and quality of life, can begin at any stage alongside cancer treatment. Clinical trials are available for every stage and may offer access to newer treatments.
The outlook varies widely with stage at diagnosis. Early-stage adenocarcinoma can sometimes be cured with surgery, but for most people with non-small cell lung cancer, current treatments do not cure the disease. As a rough guide, about 2 in 3 people with non-small cell lung cancer that has not spread beyond the lung are alive five years after diagnosis, compared with about 4 in 10 when it has reached nearby lymph nodes and about 1 in 8 when it has spread to distant organs. These figures come from people diagnosed several years ago, before some newer treatments were widely used, and cannot predict any one person's course. For many people with advanced disease, treatment becomes an ongoing part of life rather than a single course. Someone taking a targeted pill at home may keep up much of their usual routine, while chemotherapy and immunotherapy involve regular infusion visits, blood tests and regular scans to check whether the cancer is responding. Fatigue, breathlessness and treatment side effects can affect daily life, and treatment plans often change over time as the cancer responds or progresses. After treatment for early-stage cancer, follow-up visits and scans continue for years to watch for a return. Stopping smoking at any point remains worthwhile. Support from palliative care teams, counselors, social workers and lung cancer support groups can help people and families manage the physical, emotional and practical demands of the illness.
See a doctor about a cough that doesn't go away or keeps getting worse, coughing up blood, chest pain, new shortness of breath or wheezing, hoarseness, or weight loss without a clear reason, especially if you smoke or used to smoke. If you are 50 to 80 and have a significant smoking history, ask whether yearly screening is right for you. New swelling of the face or the veins of the neck, which can happen when a tumor presses on the large vein that carries blood from the head and arms back to the heart, needs prompt attention from a doctor or the care team, whether or not you are in treatment. Coughing up more than a few teaspoons of blood, or sudden severe trouble breathing, needs emergency care right away: call 911. New or worsening back or neck pain together with weakness, numbness or tingling in the legs or arms, trouble walking, or new trouble controlling the bladder or bowels can mean cancer is pressing on the spinal cord: contact your care team straight away, or get emergency care if you can't reach them quickly or the weakness is getting worse. During treatment, call your care team right away if you develop a fever of 100.5°F (38°C) or higher, chills or other signs of infection, because infections during cancer treatment can become serious quickly. If you are receiving immunotherapy, contact the team promptly about new or worsening cough or breathlessness, diarrhea, severe tiredness, yellowing of the skin or eyes, or a widespread rash.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Lung Adenocarcinoma is like, what's helped you, or ask the community a question.